TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01646515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil (Zydena)
Description: Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study: NCT03822247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Recovery Program
Description: Preoperative care:~* Patient's education~* Providing respiratory training~* Assessment of nutritional status~* Application of compression stockings~* Thromboembolism prophylaxis by low molecular weighted heparin~* Induction of hemodynamic support 12 hours before the surgery~* Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~* Maintaining normothermia~* Multimodal prevention of postoperative nausea and vomiting~* Use of spinal anesthesia~* Prevention of excessive blood loss~* Local anesthetic infiltration~Postoperative care:~* Active pain control~* Early mobilization~* Early onset of oral nutrition~* Early delirium detection~* Application of compression stockings
Study: NCT01608659

Intervention type: DRUG
Intervention: botulinum toxin Type A
Description: Previous treatment with botulinum toxin Type A for treatment of facial lines
Study: NCT02810392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Insulin
Description: Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal saline
Description: Delivery is with the Vianase device, 0.5 cc of normal saline
Study: NCT01304745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training in group
Description: Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and counseling in group
Description: Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
Study: NCT00956904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-D TRUS navigation software during T-RALP
Description: A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
Study: NCT04144556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii and conventional physical therapy
Description: This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
Study: NCT03983915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Description: Laryngeal mask was used to ensure respiration function during general anesthesia.
Study: NCT00328848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Group Treatment(patient education, self management support, caregiver support)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral
Description: patient education, self management support, caregiver support
Study: NCT00753662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1Hz TMS with H2 coil
Description: 1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
Description: 10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TMS with H2 coil
Description: SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
Study: NCT03883503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beer 5%o
Description: Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beer 8.5%o and water
Description: Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beer 8.5%o and stock
Description: Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
Study: NCT00713154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTS-01
Description: MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
Study: NCT03883503

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
Study: NCT04108624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Phase
Description: This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
Study: NCT00713154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
Study: NCT04108624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discontinuation Phase
Description: Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
Study: NCT04049136

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-proBNP
Description: Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-proBNP
Description: Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
Study: NCT01644630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented crowns
Description: The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screw-retained crowns
Description: The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
Study: NCT01520870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-299804 (Dacomitinib)
Description: Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
Study: NCT02463357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine extended release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Study: NCT01805024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omigapil
Description: Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
Study: NCT01647633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium Glycerophosphate Nasal Spray Wash
Description: Nasal wash two to six times per day
Study: NCT02958150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Practice
Study: NCT01001611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: 0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
Study: NCT01583335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle habits, including sleep and stress
Description: The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
Study: NCT01721382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study: NCT03234192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic ultra sound
Description: This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Astym Treatment Technique
Description: This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Graston Treatment Technique
Description: This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
Study: NCT01857232

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron
Description: 5HT3-antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 5HT3-antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 5HT3-antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 5HT3-antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 5HT3-antagonist
Study: NCT02463357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01857232

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Corticosteroid

Intervention type: DRUG
Group type: OTHER
Intervention: Fosaprepitant
Description: NK1 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD403 IV
Description: Amisulpride IV 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD403 IV
Description: Amisulpride IV 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD403 IV
Description: Amisulpride IV 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD403 IV
Description: Amisulpride IV 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD403 oral
Description: Amisulpride oral 10, 20 or 40 mg
Study: NCT02463357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrite
Study: NCT01857232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD403 oral
Description: Amisulpride oral 10, 20 or 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD403 oral
Description: Amisulpride oral 10, 20 or 40 mg
Study: NCT00362466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, Once daily, 5-7 years
Study: NCT02060604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac + Ranibizumab
Description: 3 monthly ranibizumab, then as needed Ketorolac TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 3 monthly ranibizumab, then as needed
Study: NCT01243879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimuli of food smell and vision
Description: 60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No stimuli of food smell and vision
Description: 60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
Study: NCT02724306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Lifestyle Programme
Study: NCT03750812

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching television
Description: Sitting and watching television for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching television
Description: Sitting and watching television for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching television
Description: Sitting and watching television for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching television
Description: Sitting and watching television for 30 minutes
Study: NCT03387839

Intervention type: OTHER
Intervention: Stress X-Ray
Description: Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion

Intervention type: OTHER
Intervention: Stress X-Ray
Description: Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion

Intervention type: OTHER
Intervention: Stress X-Ray
Description: Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
Study: NCT01537744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral 5-azacitidine in combination with romidepsin
Description: DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~1. Each cycle will last 28 days.~2. Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~3. On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~4. Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene.
Study: NCT03834701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS guided radiofrequency ablation
Description: The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
Study: NCT04299412

Intervention type: DEVICE
Intervention: DPP Fever Panel II assay
Description: Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds

Intervention type: DEVICE
Intervention: DPP Fever Panel II assay
Description: Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
Study: NCT01698047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency Class
Description: See Arm Description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: See Case Management description
Study: NCT00630279

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Microbial Lipase SLV339
Description: oral, 150 mg/d, 7 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Microbial Lipase SLV339
Description: oral, 300 mg/d, 7 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Microbial Lipase SLV339
Description: oral, 600 mg/d, 7 days treatment
Study: NCT03303378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin (Helsinn Chemical Co, Biasca, Switzerland)
Description: Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
Study: NCT04021589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weileshu
Description: a probiotics products which help to rebuild homeostasis of gut microbiome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: chemotherapy
Study: NCT00500851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic imaging for jejunal tube placement (CORTRAK)
Description: Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Endoscopic placement of jejunal feeding tubes
Study: NCT02248194

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactile electrosurgical ablation probe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial ablation
Study: NCT03675802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: giving misoprostol to this group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostone
Description: giving dinoprostine
Study: NCT04366076

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum
Description: The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
Study: NCT02188589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INEX nasal implant
Description: Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
Study: NCT03627754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg single oral dose
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg single oral dose
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg single oral dose
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.